Today at Berkeley Lab

Lab Startup Paves Path to Diabetes Treatment

The FDA approval of Takeda Pharmaceutical’s Nesina, an oral treatment for Type 2 diabetes, is the culmination of work that began with Berkeley Lab startup Syrrx. Syrrx — founded in 2000 by scientists in the Lab’s Physical Biosciences and Engineering division — offered high-throughput, rational drug discovery using robotics technology for rapid protein crystallization. Takeda acquired Syrrx in 2005 to be the pharmaceutical company’s global center for structure-based drug discovery focusing on cancer and metabolic diseases. Nesina, now approved for use in the U.S. following clinical trials, was a product of Syrrx’s unique platform. More>

You can leave a comment. View the Comment Policy.